TY  - JOUR
AU  - Wurschi, Georg W
AU  - Hinz, Andreas
AU  - Schneider, Melanie
AU  - Becker, Jan-Niklas
AU  - Frerker, Bernd
AU  - Vorbach, Samuel M
AU  - Ehret, Felix
AU  - Diefenhardt, Markus
AU  - Schunn, Fabian
AU  - von Gruben, Maria-Elena
AU  - Büttner, Marcel
AU  - Hoffmann, Elgin
AU  - Rühle, Alexander
AU  - Beier, Josephine
AU  - Ferdinandus, Simone
AU  - Trommer, Maike
AU  - Sahin, Ezgi Ceren
AU  - Hlouschek, Julian
AU  - Aninditha, Kynann
AU  - von Ohlen, Daphne Schepers
AU  - Kaufmann, Justus
AU  - Depardon, Alina
AU  - Ha, Hai Minh
AU  - Kessler, Christopher
AU  - Cieslak, Adrianna
AU  - Trommer, Simon
AU  - Fabian, Alexander
AU  - Rißner, Florian
AU  - Römer, Maximilian
AU  - Pietschmann, Klaus
TI  - Oxaliplatin-induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose-response relationship and impact on quality of life.
JO  - International journal of cancer
VL  - nn
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2026-00396
SP  - nn
PY  - 2026
N1  - #DKTKZFB26# / epub
AB  - Oxaliplatin-based regimens are increasingly used in total neoadjuvant therapy (TNT) for locally advanced rectal cancer, frequently causing dose-limiting chemotherapy-induced peripheral neuropathy (CIPN), whose extent and impact on health-related quality of life (HrQoL) remain insufficiently characterized. The optimal duration and intensity of chemotherapy within TNT for tumor response and toxicity remain unclear. This retrospective multicenter study (DRKS00033000) assessed the dose-response relationship of CIPN with cumulative oxaliplatin dose (cOXAd) and its impact on HrQoL. A total of 227 patients (164 men) with a median age of 63 (Q1-Q3: 54-68) years, who underwent oxaliplatin-based TNT between 2015 and 2024, were analyzed. HrQoL was assessed cross-sectionally during follow-up using the EORTC QLQ-C30 and QLQ-CIPN20 questionnaires. Multivariable logistic regression was applied to evaluate the relationship between cOXAd and CIPN grade ≥2, and known-group comparisons examined differences in HrQoL scores. At follow-up, 61 patients (26.9
KW  - CIPN (Other)
KW  - oxaliplatin (Other)
KW  - polyneuropathy (Other)
KW  - rectal cancer (Other)
KW  - total neoadjuvant therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41704157
DO  - DOI:10.1002/ijc.70396
UR  - https://inrepo02.dkfz.de/record/309947
ER  -